株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

C型肝炎:競合情勢、市場分析、パイプライン分析

Hepatitis C - Competitive Landscape, Market and Pipeline Analysis 2017

発行 DelveInsight Business Research LLP 商品コード 546077
出版日 ページ情報 英文 234 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.53円で換算しております。
Back to Top
C型肝炎:競合情勢、市場分析、パイプライン分析 Hepatitis C - Competitive Landscape, Market and Pipeline Analysis 2017
出版日: 2017年11月01日 ページ情報: 英文 234 Pages
概要

当レポートでは、C型肝炎治療薬について調査し、市場概要、治験段階別の製品の概要、上市済み・開発休止中の製品の評価、市場の促進要因および課題の分析などについて包括的にまとめています。

目次

  • エグゼクティブサマリー
  • 概要
  • 上市済み医薬品
  • 治験中の製品:第3相試験
  • 治験中の製品:第2相試験
  • 治験中の製品:第1章試験
  • 前臨床試験中の製品
  • 治療薬の評価:上市済みの製品
  • 治療薬の評価:開発休止中の製品
  • 市場促進要因と課題
  • 付録

図表リスト

目次
Product Code: DISR0014

DelveInsight's, "Hepatitis C - Competitive Landscape, Market and Pipeline Analysis 2017", report provides comprehensive insights about different therapeutic drugs for the treatment of Hepatitis C. A key objective of the report is to provide market and competitive landscape; and pipeline products for Hepatitis C.

The report provides in-depth details of 20+ marketed products, which are currently leading the market. It also provides the therapeutic details of the marketed product in this area, along with their historical and forecasted sales till 2022. It also covers the 15+ companies, which are active in this field with 30+ therapeutic pipeline drugs that are currently under development for the treatment of Hepatitis C including their comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Pre-clinical and Discovery stage products. Additionally, Forecasted sales of Phase III drugs are also incorporated in the report. A separate section for inactive products is also included in the report.

Comparative analysis of therapeutic drugs at various stages and their therapeutic assessment by product type and molecule type provides additional and vital details of the pipeline drugs. The report also provides the market drivers and barriers for Hepatitis C drugs for the enhanced pipeline of Hepatitis C. Information on various technologies involved in the development of pipeline therapeutics along with all the collaborations and agreements of the respective company brings added the advantage of this report. Patent and Financing details related to the products are also provided.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Table of Contents

  • Executive Summary
  • Overview
  • Marketed Drugs
  • Pipeline Therapeutics
  • Last Stage Products (Filed and Phase III)
  • Mid Stage Products (Phase II)
  • Early Stage Products (Phase I)
  • Pre-clinical and Discovery Stage Products
  • Therapeutic Assessment: Active Products
  • Inactive Products
  • Market Drivers and Barriers
  • Appendix

List of Tables

  • Table 1: Total Products for Hepatitis C
  • Table 2: Late Stage Products (Filed and Phase III)
  • Table 3: Mid Stage Products (Phase II)
  • Table 4: Early Stage Products (Phase I)
  • Table 5: Pre-clinical and Discovery Products
  • Table 6: Assessment by Monotherapy Products
  • Table 7: Assessment by Combination Therapy Products
  • Table 8: Assessment by Route of Administration
  • Table 9: Assessment by Stage and Route of Administration
  • Table 10: Assessment by Stage and Molecule Type
  • Table 11: List of Dormant Products
  • Table 12: List of Discontinued Products

List of Figures

  • Figure 1: Course of Illness with Hepatitis C
  • Figure 2: Global Epidemiology of Hepatitis C
  • Figure 3: HCV Life Cycle and Pathogenesis
  • Figure 4: Total Products for Hepatitis C
  • Figure 5: Late Stage Products (Filed and Phase III)
  • Figure 6: Mid Stage Products (Phase II)
  • Figure 7: Early Stage Products (Phase I)
  • Figure 8: Pre-clinical and Discovery Products
  • Figure 9: Assessment by Monotherapy Products
  • Figure 10: Assessment by Combination Therapy Products
  • Figure 11: Assessment by Route of Administration
  • Figure 12: Assessment by Stage and Route of Administration
  • Figure 13: Assessment by Stage and Molecule Type
  • Figure 14: Dormant Products
  • Figure 15: Discontinued Products
Back to Top